Press Releases
Therapeutic Focus
We are developing potentially curative therapies for patients by deploying our genome editing toolbox with a stepwise approach
Effectively addressing disease
Our therapeutic indications were chosen based on our conviction in the underlying biology, existence of validating preclinical and clinical data, availability of pharmacodynamic and translational tools to assess early proof-of-concept, relevant value supporting outcome measures, and, most importantly, ongoing clinical unmet need. These programs are selected to both address devastating diseases and to establish new standards in targetability, precision, efficiency, and scope of editing capabilities. Using our toolbox, we aim to match the optimal genome editing tool to each indication to ensure lasting effects on the lives of patients.
Therapeutic Focus
Discovery
PreClinical
Phase 1
Phase 2
Phase 3
Partner
In vivo
Discovery
PreClinical
Phase 1
Phase 2
Phase 3
-
-
An illustrated depiction of a human liver, targeting Hemophilia A, PreClinical 50% completed
-
An illustrated depiction of a human liver, targeting Primary Hyperoxaluria Type 1, PreClinical 50% completed, in partnership with Moderna
-
An illustrated depiction of a human liver, targeting Transthyretin Amyloidosis, PreClinical 50% completed, in partnership with Ionis
-
An illustrated depiction of a human liver, targeting Cardiovascular Disease, Discovery 100% completed, in partnership with Ionis
-
An illustrated depiction of a human liver, targeting Alpha-1 Antitrypsin Deficiency, Discovery 50% completed
-
An illustrated depiction of a human liver, targeting Wilson's Disease, Discovery 50% completed
-
-
-
An illustrated depiction of a human brain, targeting Familial ALS, Discovery 50% completed
-
An illustrated depiction of a human brain, targeting Spontaneous ALS, Discovery 50% completed
-
An illustrated depiction of a human brain, targeting Charcot-marie-tooth disease type 1a, Discovery 50% completed
-
An illustrated depiction of a human brain, targeting Duchenne Muscular Dystrophy, Discovery 50% completed
-
-
-
An illustrated depiction of a human lung, targeting Cystic Fibrosis, Discovery 50% completed
-
Ex vivo
Discovery
PreClinical
Phase 1
Phase 2
Phase 3
-
-
An illustrated depiction of a human cell, targeting Immuno-oncology (TCR; CAR-T Cells), PreClinical 100% completed, in partnership with Affini-T
-
An illustrated depiction of a human cell, targeting Autoimmune (Car-T Cells), Discovery 50% completed
-
Partnering with Pioneers
-
11.14.22 -
Press Releases
06.15.22 Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients
-
Press Releases
11.02.21 Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics
Leveraging next-generation gene editing tools to generate a broad and differentiated therapeutic approach
With our toolbox, we can edit any target in the human genome.